(via NewsDirect)
COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the
![](https://public.newsdirect.com/621792445/S5dy92rv.png)
5 Biotech and Pharma Companies Spearheading Viral Tripledemic
The first company that everyone thinks of when considering COVID-19 solutions is
![](https://public.newsdirect.com/621792445/MJZ8uxOc.png)
Big Pharma competitors GSK (NYSE: GSK) and Roche are also key players in the tripledemic race. Roche was the initial innovator of the influenza antiviral blockbuster, Tamiflu, but the company has made recent progress with COVID, too. The company is well known for its IL-6 inhibitor (an anti-inflammatory monoclonal antibody) approval in severe COVID-19. For next steps against influenza, the company has developed a new therapeutic called baloxavir marboxil, aka Xofluza, which unfortunately has some severe drawbacks in causing drug resistance mutations at quite a high rate such that it’s not necessarily a good choice for kids. This could derail its blockbuster follow-up to the Tamiflu success seen years ago. Roche is certainly outshined by
GSK’s progress is more straightforward. Known for its prowess in the antiviral space, GSK was granted a priority review and PDUFA date of
One smaller company,
The company’s secret sauce lies in its VLP (virus-like particle), which allows viral proteins to be assembled more similarly to an actual virus and is supposed to improve the immune response compared to vaccines that use these proteins alone, like mRNA vaccines. The company recently hit the headlines with positive phase 1 clinical trial results for its RSV vaccine with sustained neutralizing antibody responses through 6 months; durability of response was a key reason for developing VLP vaccines.
Unfortunately, for common yearly diseases like COVID, influenza, and RSV, vaccines are only a partial answer. Another small pharma company, Bioxytran Inc. (OTCMKTS: BIXT), might have antiviral treatment solutions for all three viruses. Bioxytran recently released slam-dunk results from their ProLectin-M antiviral, which had a 100% response rate reducing the viral load of COVID-19 patients to undetectable levels in just a few days, effectively curing every single patient on the drug. These results are unprecedented and quite possibly the best COVID antiviral results ever recorded. The company’s drugs are made using carbohydrate chemistry which usually means a benign safety profile. Unbeknownst to most investors, the company appears to be working on or considering treating other viruses including influenza and RSV, and if BIXT can show its RSV and influenza antivirals work like its COVID antiviral, then the company would have multiple potential blockbuster products. ProLectin-M is a phase 3 ready drug with results expected in 2023.
Conclusion
These leading tripledemic companies are focusing on the current and future problems facing the nation. But when it comes to investment risk and reward, there are two clear winners. With respect to the bigger pharma companies with established sales,
However, multi-bagger returns are unlikely to be seen with big pharma. Bioxytran, however, appears to be a smaller biotech that could return multiples to investors. Big Pharma is licensing COVID-19 antiviral candidates from various biotech companies for hundreds of millions in deal value, and some of these companies are already worth that in market capitalization. When considering the value of each of the companies, Bioxytran stands out with just a
Investors might consider a dual investment in PFE and BIXT to take advantage of the tripledemic and bolster portfolio returns.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. RazorPitch is responsible for the production and distribution of this content. RazorPitch is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. RazorPitch authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. RazorPitch has not been compensated to produce this content. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website.
Contact Details
RazorPitch
+1 585-301-7700
Mark@RazorPitch.com
Company Website
http://razorpitch.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source